A IMPORTÂNCIA DA ATENÇÃO FARMACÊUTICA FRENTE A NÃO ADESÃO AO TRATAMENTO E A RESISTÊNCIA VIROLÓGICA AO HIV
暂无分享,去创建一个
[1] Karen Sarmento Costa,et al. Pharmaceutical care in Brazil’s primary health care , 2017, Revista de saude publica.
[2] Cléa Adas Saliba Garbin,et al. Adesão à terapia antirretroviral em pacientes HIV soropositivos no Brasil: uma revisão da literatura , 2017 .
[3] J. Hardin,et al. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy , 2016, Pharmacotherapy.
[4] N. Ford,et al. Sustaining the future of HIV counselling to reach 90-90-90: a regional country analysis , 2016, Journal of the International AIDS Society.
[5] D. Podzamczer,et al. Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial , 2015, Journal of acquired immune deficiency syndromes.
[6] Inês Dourado,et al. Factors associated with non-adherence to antiretroviral therapy in adults with AIDS in the first six months of treatment in Salvador, Bahia State, Brazil. , 2015, Cadernos de saude publica.
[7] Danielly Barreto de Souza Neves,et al. ASSISTÊNCIA FARMACÊUTICA NO SUS: OS DESAFIOS DO PROFISSIONAL FARMACÊUTICO , 2015 .
[8] C. Delaugerre,et al. Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial. , 2014, The Lancet. Infectious diseases.
[9] N. Ford,et al. Systematic review and meta‐analysis: Patient and programme impact of fixed‐dose combination antiretroviral therapy , 2014, Tropical medicine & international health : TM & IH.
[10] R. Haubrich,et al. Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study , 2014, The Journal of infectious diseases.
[11] J. Stephens,et al. The Prevalence of Transmitted Resistance to First-Generation Non-Nucleoside Reverse Transcriptase Inhibitors and Its Potential Economic Impact in HIV-Infected Patients , 2013, PloS one.
[12] B. Clotet,et al. Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. , 2013, The Lancet. Infectious diseases.
[13] C. Charpentier,et al. Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] R. Leavitt,et al. Safety and efficacy of raltegravir in patients with HIV‐1 and hepatitis B and/or C virus coinfection , 2012, HIV medicine.
[15] I. Gurgel,et al. Trabalho em equipe e interdisciplinaridade: desafios para a efetivação da integralidade na assistência ambulatorial às pessoas vivendo com HIV/Aids em Pernambuco , 2012 .
[16] S. Doucette,et al. Discontinuation of Pneumocystis jirovecii Pneumonia Prophylaxis with CD4 Count <200 Cells/µL and Virologic Suppression: A Systematic Review , 2011, PloS one.
[17] Lynne Peeples,et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. , 2009, The New England journal of medicine.
[18] D. Fine,et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment , 2009, AIDS.
[19] P. Naidoo,et al. Exploring the use of novel drug delivery systems for antiretroviral drugs. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[20] E. Delaporte,et al. Long-term efficacy and tolerance of efavirenz- and nevirapine-containing regimens in adult HIV type 1 Senegalese patients. , 2008, AIDS research and human retroviruses.
[21] B. Gazzard,et al. Tenofovir Disoproxil Fumarate, Emtricitabine, and Efavirenz Compared With Zidovudine/Lamivudine and Efavirenz in Treatment-Naive Patients: 144-Week Analysis , 2008, Journal of acquired immune deficiency syndromes.
[22] Louise V Wain,et al. Adaptation of HIV-1 to its human host. , 2007, Molecular biology and evolution.
[23] Joel E Gallant,et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. , 2006, The New England journal of medicine.
[24] D. Paterson,et al. Measurement of Adherence to Antiretroviral Medications , 2002, Journal of acquired immune deficiency syndromes.
[25] D. Ho,et al. Genetic characterization of new West African simian immunodeficiency virus SIVsm: geographic clustering of household-derived SIV strains with human immunodeficiency virus type 2 subtypes and genetically diverse viruses from a single feral sooty mangabey troop , 1996, Journal of virology.